Recommendations for selection and adaptation of rating scales for clinical studies of rapid-acting antidepressants.
Frontiers in Psychiatry 2023 Christian Yavorsky, Elizabeth D. Ballard, Mark Opler et al. 7 citations
The novel mechanisms of action (MOA) derived from some recently introduced molecular targets have led to regulatory approvals for rapid acting antidepressants (RAADs) that can generate responses within hours or days, rather than weeks or months. These novel targets include the N-methyl-D-glutamate receptor antagonist ketamine, along with its enantiomers and various derivatives, and the...